Novel targets for antibiotics in Staphylococcus aureus

Future Microbiology

Volumn 2, Issue 6, 2007, Pages 655-666

  Ohlsen, Knut ^a   Lorenz, Udo ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Antibiotic resistance; Gram positive pathogens; Immunotherapy; MRSA; New targets; Novel antibacterials; Staphylococcus areus

Indexed keywords

3 OXOACYL ACYL CARRIER PROTEIN SYNTHASE; ADHESIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CERULENIN; DALBAVANCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE IV; ENDOPEPTIDASE CLP; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); FTSZ PROTEIN; GENE PRODUCT; ISONIAZID; N [1 TERT BUTYL 2 OXO 2 [4 (2 THIAZOLYLMETHYL) 1 PIPERAZINYL]ETHYL] 3 CYCLOPENTYL 2 (N FORMYL N HYDROXYAMINOMETHYL)PROPIONAMIDE; NEW DRUG; ORITAVANCIN; PEPTIDE DEFORMYLASE; PEPTIDE DEFORMYLASE INHIBITOR; PEPTIDOGLYCAN GLYCOSYLTRANSFERASE; PLATENCIN; PLATENSIMYCIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; STAPHYLOCOCCUS VACCINE; TEICHOIC ACID; THIOREDOXIN; THIOREDOXIN REDUCTASE; TRICLOSAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE; VIRIDITOXIN;

ACTIVE IMMUNIZATION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL CELL WALL; BACTERIAL VIRULENCE; CELL FUNCTION; CLINICAL TRIAL; DRUG TARGETING; FATTY ACID SYNTHESIS; HOSPITAL INFECTION; HUMAN; IMMUNOTHERAPY; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 37549061026     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.2.6.655     Document Type: Review

References (102)

1. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32, 470-485 (2004).
2. Tiemersma EW, Bronzwaer SL, Lyytikainen O et al.: Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg. Infect. Dis. 10, 1627-1634 (2004).
3. Moran GJ, Krishnadasan A, Gorwitz RJ et al.: Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355, 666-674 (2006).
4. Tsiodras S, Gold HS, Sakoulas G et al.: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207-208 (2001).
5. Weigel LM, Clewell DB, Gill SR et al.: Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302, 569-1571 (2003).
6. Tenover FC, Weigel LM, Appelbaum PC et al.: Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48, 275-280 (2004).
7. Glass JI, Assad-Garcia N, Alperovich N et al.: Essential genes of a minimal bacterium. Proc. Natl Acad. Sci. USA 103, 425-430 (2006).
8. Salama NR, Shepherd B, Falkow S: Global transposon mutagenesis and essential gene analysis of Helicobacter pylori. J. Bacteriol. 186, 7926-7935 (2004).
9. Song JH, Ko KS, Lee JY et al.: Identification of essential genes in Streptococcus pneumoniae by allelic replacement mutagenesis. Mol. Cells 19, 365-374 (2005).
10. Kobayashi K, Ehrlich SD, Albertini A et al.: Essential Bacillus subtilis genes. Proc. Natl Acad. Sci. USA 100, 4678-4683 (2003).
11. Forsyth RA, Haselbeck RJ, Ohlsen KL et al.: A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol. Microbiol. 43, 1387-1400 (2002).
12. Ji Y, Zhang B, Van SF et al.: Identification of critical Staphylococcal genes using conditional phenotypes generated by antisense RNA. Science, 293, 2266-2269 (2001).
13. Zalacain M, Biswas S, Ingraham KA et al.: A global approach to identify novel broad-spectrum antibacterial targets among proteins of unknown function. J. Mol. Microbiol Biotechnol. 6, 109-126 (2003).
14. Jana M, Luong TT, Komatsuzawa H et al.: A method for demonstrating gene essentiality in Staphylococcus aureus. Plasmid 44, 100-104 (2000).
15. Zhang L, Fan F, Palmer LM et al.: Regulated gene expression in Staphylococcus aureus for identifying conditional lethal phenotypes and antibiotic mode of action. Gene 255, 297-305 (2000).
16. Rohrer S, Ehlert K, Tschierske M, Labischinski H, Berger-Bachi B: The essential Staphylococcus aureus gene fmhB is involved in the first step of peptidoglycan. pentaglycine interpeptide formation. Proc. Natl Acad. Sci. USA, 96, 9351-9356 (1999).
17. Ji Y, Marra A, Rosenberg M, Woodnutt G: Regulated antisense RNA eliminates α-toxin virulence in Staphylococcus aureus infection. J. Bacteriol. 181, 6585-6590 (2001).
18. Streker K, Freiberg C, Brötz-Oesterhelt H et al.: In vitro and in vivo characterization of novel antibiotics targets from Staphylococcus aureus. Antimicrob. Agents Chemother. (2007) (In press).
19. Becker D, Selbach M, Rollenhagen C et al.: Robust Salmonella metabolism limits possibilities for new antimicrobials. Nature 440, 303-307 (2006).
20. Wang J, Galgoci A, Kodali S et al.: Discovery of a small molecule that inhibits cell division by blocking FtsZ, a novel therapeutic target of antibiotics. J. Biol. Chem. 278, 44424-44428 (2003).
21. Margalit DN, Romberg L, Mets RB et al.: Targeting call division: small-molecule inhibitors of FtsZ GTPase perturb cytokinetic ring assembly and induce bacterial lethality. Proc. Natl Acad. Sci. USA 101, 11821-11826 (2004).
22. Yuan Z, White RJ: The evolution of peptide deformylase as a target: contribution of biochemistry, genetics and genomics. Biochem Pharmacol. 71, 1042-1047 (2006).
23. Chen D, Yuan Z: Therapeutic potential of peptide deformylase inhibitors. Expert Opin. Investig. Drugs 14, 1107-1116 (2005).
24. Lee MD, She Y, Soskis MJ et al.: Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. J. Clin. Invest. 114, 1107-1116 (2004).
25. Yoon HJ, Kim HL, Lee SK et al.: Crystal structure of peptide deformylase from Staphylococcus aureus in complex with actinonin, a naturally occurring antibacterial agent. Proteins 57, 639-642 (2004).
26. Hackbarth CJ, Chen DZ, Lewis JG et al.: N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother. 46, 2752-2764 (2002).
27. Chen D, Hackbarth C, Ni ZJ et al.: Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach. Antimicrob. Agents Chemother. 48, 250-261 (2004).
28. Ramanathan-Girish S, McColm J, Clements JM et al.: Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob. Agents Chemother. 48, 4835-4842 (2004).
29. Dubail I, Bigot A, Lazarevic V et al.: Identification of an essential gene of Listeria monocytogenes involved in teichoic acid biogenesis. J BacterioL 188, 6580--6591 (2006).
30. Bhavsar AP, Erdman LK, Schertzer JW, Brown ED: Teichoic acid is an essential polymer in Bacillus subtilis that is functionally distinct from teichuronic acid. J Bacteriol. 186, 7865-7873 (2004).
31. D'Elia MA, Millar KE, Beveridge TJ, Brown ED: Wall teichoic acid polymers are dispensable for cell viability in Bacillus subtilis. J. Bacteriol. 188, 8313-8316 (2006).
32. D'Elia MA, Pereira MP Chung YS et al.: Lesions in teichoic acid biosynthesis in Staphylococcus aureus lead to a lethal gain of function in the otherwise dispensable pathway. J. Bacteriol. 188, 4183-4189 (2006).
33. Weidenmaier C, Kokai-Kun JF, Kristian SA et al.: Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat. Med. 10, 243-245 (2004).
34. Weidenmaier C, Peschel A, Kempf VA, Lucindo N, Yeaman MR, Bayer AS: DltABCD- and MprF-mediated cell envelope modifications of Staphylococcus aureus confer resistance to platelet microbicidal proteins and contribute to virulence in a rabbit endocarditis model. Infect. Immun. 73, 8033-8038 (2005).
35. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL: Drugs far bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007).
36. Uziel O, Borovok I, Schreiber R, Cohen G, Aharonowitz Y: Transcriptional regulation of the Staphylococcus aureus thioredoxin and thioredoxin reductase genes in response to oxygen and disulfide stress. J. Bacteriol. 186, 326-334 (2004).
37. Cregg KM, Wilding I, Black MT: Molecular cloning and expression of the spsB gene encoding an essential type I signal peptidase from Staphylococcus aureus. J. Bacterial. 178, 5712-5718 (1996).
38. Garmory HS, Titball RW. ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies. Infect. Immun. 72, 6757-6763 (2004).
39. +-dependent DNA ligase from Staphylococcus aureus J. Bacteriol. 183, 3016-3024 (2001).
40. Sun J, Zheng L, Landwehr C, Yang J, Ji Y: Identification of a novel essential two-component signal transduction system, YhcSR, in Staphylococcus aureus. J. Bacteriol. 187, 7876-7880 (2005).
41. Zheng L, Yang J, Landwehr C, Fan F, Ji Y: Identification of an essential glycoprotease in Staphylococcus aureus. FEMS Microbiol. Lett. 245, 279-285 (2005).
42. Dubrac S, Msadek T: Identification of genes controlled by the essential YycG/YycF two-component system of Staphylococcus aureus. J Bacteriol. 186, 1175-1181 (2004).
43. Bruton G, Huxley A, O'Hanlon PJ et al.: Lipopeptide substrates for SpsB, the Staphylococcus aureus type I signal peptidase: design, conformation and conversion to ketoamide inhibitors. Eur. J Med. Chem. 38, 351-356 (2003).
44. Payne DJ, Miller WH, Berry V et al.: Discovery of a novel and potent class of Fabl-directed antibacterial agents. Antimicrob. Agents Chemother. 46, 3118-3124 (2002).
45. Wang J, Soisson SM, Young K et al.: Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441, 358-361 (2006).
46. Wang J, Kodali S, Lee SH et al.: Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc. Natl Acad. Sci. USA 104, 7612-7616 (2007).
47. Moir DT: Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase. Curr. Drug Targets Infect. Disord. 5, 297-305 (2005).
48. Ton-That H, Labischinski H, Berger-Bachi B, Schneewind O: Anchor structure of staphylococcal surface proteins. III. Role of the FemA, FemB, and FemX factors in anchoring surface proteins to the bacterial cell wall. J. Biol. Chem. 273, 29143-29149 (1998).
49. Lovering AL, de Castro LH, Lim D, Strynadka NC: Structural insight into the transglycosylation step of bacterial cell-wall biosynthesis. Science 315, 1402-1405 (2007).
50. Harris MS, Herberg JT, Cialdella JI et al.: Crystallization and preliminary x-ray analysis of UDP-N-acetylenolpyruvylglucosamine reductase (MurB) from Staphylococcus aureus. Acta Crystallogr. D. Biol. Crystallogr. 57, 1032-1035 (2001).
51. Koch AL: Bacterial wall as target for attack: past, present, and future research. Clin. Microbiol. Rev. 16, 673-687 (2003).
52. Breukink E, de Kruijff B: Lipid II as a target for antibiotics. Nat. Rev. Drug Discov. 5, 321-332 (2006).
53. Beyer D, Kroll HP, Endermann R et al.: New class of bacterial phenylalanyl-tRNA synthetase inhibitors with high potency and broad-spectrum activity. Antimicrob. Agents Chemother. 2004, 48, 525-532 (2004).
54. Hurdle JG, O'Neill AJ, Chopra I: Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. Antimicrob. Agents Chemother. 49, 4821-4833 (2005).
55. Ochsner UA, Sun X, Jarvis T. Critchley I, Janjic N: Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents. Expert Opin. Investig. Drugs 16, 573-593 (2007).
56. Henkel T, Finlay J: Emergence of resistance during mupirocin treatment: is it a problem in clinical practice? J. Chemother. 11, 331-337 (1999).
57. Grossman TH, Barrels DJ, Mullin S et al.: Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob. Agents Chemother. 51, 657-666 (2007).
58. Mani N, Gross CH, Parsons JD et al.: In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrob. Agents Chemother. 50, 1228-1237 (2006).
59. Projan SJ, Nesin M, Dunman PM: Staphylococcal vaccines and immunotherapy: to dream the impossible dream? Curr. Opin. Pharmacol 6, 473-479 (2006).
60. Götz F: Staphylococci in colonization and disease: prospective targets for drugs and vaccines. Curr. Opin. Microbiol. 7, 477-487 (2004).
61. Foster TJ, Höök M: Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 6, 484-488 (1998).
62. Rivas JM, Speziale P, Patti JM, Höök M: MSCRAMM-targeted vaccines and immunotherapy for staphylococcal infection. Curr. Opin. Drug Discov. Devel. 7, 223-227 (2004).
63. Vernachio, JH, Bayer AS, Ames B et al.: Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphyloccus aureus and Staphyloccus epidermidis infections in vivo. Antimicrob. Agents Chemother. 50, 511-518 (2006).
64. Bloom BT INH-A21: a donor-selected staphylococcal human immune globulin for the prevention of law-onset neonatal staphylococcal infection. Expert Opin. Investig. Drugs 15, 703-707 (2006).
65. Kaufman D: Veronate (Inhibitex®). Curr Opin. Investig. Drug 7, 172-179 (2006).
66. Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX®, a polysaccharide conjugate vaccine against S. aureus infection: from die lab bench to Phase III clinical trials. Vaccine 22, 880-887 (2004).
67. Verdier I, Durand G, Bes M et al.: Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests. J. Clin. Microbiol. 45, 725-729 (2007).
68. von Eiff C, Taylor KL, Mellmann A et al.: Distribution of capsular and surface polysaccharide serotypes of Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 58, 297-302 (2007).
69. Weems JJ Jr, Steinberg JP, Filler S et al.: Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50, 2751-2755 (2006).
70. Reilley S, Wenzel E, Reynolds L, Bennett B, Patti JM, Hetherington S: Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers. Antimicrob. Agents Chemother. 49, 959-962 (2005).
71. Patti JM: A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 22(Suppl. 1), S39-S43 (2004).
72. Burnie JP Matthews RC, Carter T et al.: Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect. Immun. 68, 3200-3209 (2000).
73. Baker M: Anti-infective antibodies: finding the path forward. Nat. Biotechnol. 24, 1491-1493 (2006).
74. Zhou H, Xiong ZY, Li HP, Zheng YL, Jiang YQ. An immunogenicity study of a newly fusion protein Cna-FnBP vaccinated against Staphylococcus aureus infections in a mice model. Vaccine 24, 4830-4837 (2006).
75. Schaffer AC, Solinga RM, Cocchiaro J et al.: Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect. Immun. 74, 2145-2153 (2006).
76. Kuklin NA, Clark DJ, Secore S et al.: A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus; macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun. 74, 2215-2223 (2006).
77. Gaudreau MC, Lacasse P, Talbot BG: Protective immune responses to a multi-gene DNA vaccine against Staphylococcus aureus. Vaccine 25, 814-824 (2007).
78. Stranger-Jones YK, Bae T, Schneewind O: Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl Acad. Sci. USA 103, 16942-16947 (2007).
79. Maira-Litran T, Kropec A, Goldmann DA, Pier GB: Comparative opsonic and protective activities of Staphylacoccus aureus conjugate vaccines containing native or deacetylated staphylococcal poly-N-acetyl-β-(1-6)-glucosamine. Infect. Immun. 73, 6752-6762 (2005).
80. Chavakis T, Wiechmann K, Preissner KF Herrmann M: Staphylacoccus aureus interactions with the endothelium: the role of bacterial 'secretable expanded repertoire adhesive molecules' (SERAM) in disturbing host defense systems. Thromb. Haemost. 94, 278-285 (2005).
81. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr: Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38, 1279-1286 (2004).
82. Projan SJ: Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427-430 (2003).
83. Norrby SR, Nord CE, Finch R: Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5, 115-119 (2005).
84. Kopp U, Roos M, Wecke J, Labischinski H: Staphylococcal peptidoglycan interpeptide bridge biosynthesis: a novel antistaphylococcal target? Microb. Drug Resist. 2, 29-41 (1996).
85. Liu S, Chang JS, Herberg JT et al.: Allosteric inhibition of Staphylococcus aureus D-alanine:D-alanine ligase revealed by crystallographic studies. Proc. Natl Acad. Sci. USA 103, 15178-15183 (2006).
86. Zheng L, Yu C, Bayles K, Lasa I, Ji Y: Conditional mutation ofan essential putative glycoprotease eliminates autolysis in Staphylococcus aureus. J. Bacteriol. 189, 2734-2742 (2007).
87. Brötz-Oesterhelt H, Beyer D, Kroll HP et al.: Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat. Med. 11, 1082-1087 (2005).
88. +-dependent DNA ligase by pyridochromanones. J. Biol. Chem. 278, 39435-39442 (2003).
89. Lee JC, Park JS, Shepherd SE, Carey V Fattom A: Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect. Immun. 65, 4146-4151 (1997).
90. O'Riordan K, Lee JC: Staphylococcus aureus capsular polysaccharides. Clin. Microbiol. Rev. 17, 218-234 (2004).
91. Clarke SR, Brummell KJ, Horsburgh MJ et al.: Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J. Infect. Dis. 193, 1098-1108 (2006).
92. Kelly-Quintos C, Cavacini LA, Posner MR, Goldmann D, Pier GB: Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine. Infect. Immun. 74, 2742-2750 (2006).
93. Rennermalm A, Li YH, Bohaufs L et al.: Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat. Vaccine 19, 3376-3383 (2001).
94. Shkreta L, Talbot BG, Diarra MS, Lacasse P: Immune responses to a DNA/ protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows. Vaccine 23, 114-126 (2004).
95. Menzies BE: The role of fibronectin binding proteins in the pathogenesis of Staphylococcus aureus infections. Curr. Opin Infect. Dis. 16, 225-229 (2003).
96. Ladhani S: Understanding the mechanism of action of the exfoliative toxins of Staphylococcus aureus. FEMS Immunol. Med. Microbiol. 39, 181-189 (2003).
97. McCormick JK, Yarwood JM, Schlievert PM: Toxic shock syndrome and bacterial superantigens: an update. Annu. Rev. Microbiol. 55, 77-104 (2001).
98. Ferry T, Perpoint T, Vandenesch F, Etienne J: Virulence determinants in Staphylococcus aureus and their involvement in clinical syndromes. Curr. Infect. Dis. Rep. 7, 420-428 (2005).
99. Nilsson IM, Hartford O, Foster T, Tarkowski A: α-toxin and γ-toxin jointly promote Staphylococcus aureus virulence in routine septic arthritis. Infect. Immun. 67, 1045-1049 (1999).
100. Gillet Y, Issartel B, Vanhems P et al.: Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359, 753-759 (2002).
101. De Kimpe SJ, Kengatharan M, Thiemermann C, Vane JR: The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc. Natl Acad. Sci. USA 92, 10359-10363 (1995).
102. Lorenz U, Ohlsen K, Karch H, Hecker M, Thiede A, Hacker J: Human antibody response during sepsis against targets expressed by methicillin resistant Staphylococcus aureus. FEMS Immunol. Med. Microbiol. 29, 145-153 (2000).